
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc. demonstrated robust financial performance with a 21% top-line growth in Q3, driven by a 13% increase in volumes and a 5% rise in average selling prices (ASPs), along with record cash collections in October. The company significantly expanded its sales force by approximately 50%, which is expected to further enhance volume growth, particularly following a notable 19% year-over-year increase in kidney surveillance volumes reported in Q2'25. Additionally, CareDx achieved GAAP net income positivity and raised its financial guidance, contributing to a positive market reaction with a 10% rise in the stock price.
Bears say
CareDx Inc. has reported a volume of 50,000 for Q3'25, reflecting a 13% year-over-year growth but falling short of expectations, indicating potential limitations in growth momentum and market dynamics. The company's shares have faced downward pressure, trading at a significant discount to historical averages, with current valuations at 1.4 times the projected $415 million revenue for 2026, compared to the diagnostics sector's higher multiples. Concerns regarding CareDx’s ability to successfully commercialize new diagnostic solutions and instability due to management changes over the past three years further contribute to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares